RxDoctor Payments DataLook up a doctor →

Myron Brand, MD

Gastroenterology · New Haven, CTNPI 1336280080

Payments from drug & device makers

$60,397in general payments, 2019–2025

Across 536 payments — averaging $112.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$24K
  • AbbVie$19K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • Intercept Pharmaceuticals, Inc.$4K
  • Alfasigma USA, Inc.$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$6001%
  • Speaking & faculty fees$48,03080%
  • Travel & lodging$2,0663%
  • Food & beverage$9,55816%
  • Education$1430%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,397 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$331,731
Medicare patients
330
Services billed
11,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab49$1,313,362
GattexTeduglutide13$601,865
RinvoqUpadacitinib31$360,484
Humira(Cf) PenAdalimumab29$339,282
CreonLipase/Protease/Amylase22$140,522
Mesalamine202$127,675
Dupixent SyringeDupilumab14$104,782
Dexlansoprazole DrDexlansoprazole71$28,562
LinzessLinaclotide13$16,610
Budesonide ErBudesonide13$16,482
VemlidyTenofovir Alafenamide12$15,843
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates150$8,953
UcerisBudesonide11$8,384
MotegrityPrucalopride Succinate12$7,599
DexilantDexlansoprazole17$7,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$686$1,313,36249 claims
Takeda Pharmaceuticals U.S.A., Inc.Gattex, Motegrity, Dexilant$6,431$616,98242 claims
AbbVieRinvoq, Creon, Linzess$19,276$517,61566 claims
GileadVemlidy$23,840$15,84312 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCUceris$1,073$8,38411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →